Oligodendroglioma: Difference between revisions

Jump to navigation Jump to search
No edit summary
(29 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''.
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''.
{{Infobox_Disease |
  Name          = {{PAGENAME}} |
  Image          = |
  Caption        = |
  DiseasesDB    = 29450 |
  ICD10          = C71 |
  ICD9          = {{ICD9|191.9}} |
  ICDO          = 9450/3-9451/3 |
  OMIM          = |
  MedlinePlus    = |
  MeshID        = D009837 |
}}
{{Oligodendroglioma}}
{{Oligodendroglioma}}
{{CMG}}
{{CMG}}{{AE}}{{S.M.}}{{MJM}}, {{SR}}


{{EH}}
{{SK}} Oligodendroglial tumor; oligodendroglial neoplasm; neoplasm of the oligodendroglia; oligodendroglial cancer; cancer of the oligodendroglia; oligodendroma; OD; ODs; oligoastroglioma; oligodendroblastoma


==[[Oligodendroglioma overview|Overview]]==
==[[Oligodendroglioma overview|Overview]]==


==[[Oligodendroglioma historical perspective|Historical Perspective]]==
==[[Oligodendroglioma historical perspective|Historical Perspective]]==
==[[Oligodendroglioma classification|Classification]]==


==[[Oligodendroglioma pathophysiology|Pathophysiology]]==
==[[Oligodendroglioma pathophysiology|Pathophysiology]]==
==[[Oligodendroglioma causes|Causes]]==
==[[Oligodendroglioma differential diagnosis|Differentiating Oligodendroglioma from other Diseases]]==


==[[Oligodendroglioma epidemiology and demographics|Epidemiology & Demographics]]==
==[[Oligodendroglioma epidemiology and demographics|Epidemiology & Demographics]]==
Line 30: Line 24:
==[[Oligodendroglioma screening|Screening]]==
==[[Oligodendroglioma screening|Screening]]==


==[[Oligodendroglioma causes|Causes]]==
==[[Oligodendroglioma natural history, complications, and prognosis|Natural History, Complications, and Prognosis]]==
 
==[[Oligodendroglioma differential diagnosis|Differentiating Oligodendroglioma]]==
 
==[[Oligodendroglioma natural history|Complications & Prognosis]]==


==Diagnosis==
==Diagnosis==
[[Oligodendroglioma history and symptoms|History and Symptoms]] | [[Oligodendroglioma physical examination|Physical Examination]] | [[Oligodendroglioma staging|Staging]] | [[Oligodendroglioma laboratory tests|Laboratory tests]] | [[Oligodendroglioma electrocardiogram|Electrocardiogram]] | [[Oligodendroglioma x ray|X Rays]] | [[Oligodendroglioma CT|CT]] | [[Oligodendroglioma MRI|MRI]] [[Oligodendroglioma echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Oligodendroglioma other imaging findings|Other images]] | [[Oligodendroglioma other diagnostic studies|Alternative diagnostics]]
[[Oligodendroglioma staging|Staging]] | [[Oligodendroglioma history and symptoms|History and Symptoms]] | [[Oligodendroglioma physical examination|Physical Examination]] | [[Oligodendroglioma laboratory tests|Laboratory Findings]] | [[Oligodendroglioma chest x ray|Chest X Ray]] | [[Oligodendroglioma CT|CT]] | [[Oligodendroglioma MRI|MRI]] | [[Oligodendroglioma ultrasound|Ultrasound]] | [[Oligodendroglioma other imaging findings|Other Imaging Findings]] | [[Oligodendroglioma other diagnostic studies|Other Diagnostic Studies]]


==Treatment==
==Treatment==
[[Oligodendroglioma medical therapy|Medical therapy]] | [[Oligodendroglioma surgery|Surgical options]] | [[Oligodendroglioma primary prevention|Primary prevention]] | [[Oligodendroglioma secondary prevention|Secondary prevention]] | [[Oligodendroglioma cost-effectiveness of therapy|Financial costs]] | [[Oligodendroglioma future or investigational therapies|Future therapies]]
[[Oligodendroglioma medical therapy|Medical therapy]] | [[Oligodendroglioma surgery|Surgery]] | [[Oligodendroglioma primary prevention|Primary Prevention]] | [[Oligodendroglioma secondary prevention|Secondary Prevention]] | [[Oligodendroglioma cost-effectiveness of therapy|Cost-Effeciveness of Therapy]] | [[Oligodendroglioma future or investigational therapies|Future or Investigational Therapies]]
 
==Histopathological Grading==
 
The histopathologic grading of oligodendrogliomas is controversial.  Currently the most commonly used grading schema is based on year 2007 [[World Health Organization]] (WHO) guidelines.  Oligodendrogliomas are generally dichotomized into grade II (low grade) and grade III (high grade) tumors.  The designation of grade III oligodendroglioma (high grade) generally subsumes the previous diagnoses of anaplastic or malignant oligodendroglioma. 
 
Unfortunately, the WHO guidelines include subjective criteria in differentiating grade II and grade III tumors including the appreciation of “significant” hypercellularity and pleomorphism in the higher grade lesion.  In addition, the presence of low mitotic activity, vascular proliferation and necrosis, including pseudopallisading necrosis are insufficient by themselves to elevate the grade of these tumors.  This leads to inevitable interobserver variability in diagnosis by pathologists.  The ultimate responsibility for making treatment decisions and interpretation of these diagnoses lies with the oncologist in consultation with the patient and their family.   
 
It has been proposed that [[World Health Organization|WHO]] guidelines should contain a category for grade IV oligodendrogliomas which essentially appear to be glial neoplasms with overwhelming features of [[glioblastoma multiforme]] (GBM) arising from known lower grade oligodendrogliomas or GBM with a significant proportion of oligodendroglial differentiation.  The diagnostic ultility of this latter category is uncertain as these tumors may behave either like glioblastoma or grade III oligodendrogliomas.  As such, this is an exceptionally unusual diagnosis. 
 
The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as ‘glioblastoma with oligodendroglioma component’. <ref>{{cite journal |author=Louis D, Ohgaki H, Wiestler O, 'et al'' |title=The 2007 WHO Classification of Tumours of the Central Nervous System |journal=Acta Neuropathologica |volume=114 |issue=2 |pages=97-109 |year=2007 |pmid=17618441 |doi=10.1007/s00401-007-0243-4}}</ref> It remains to be established whether or not these tumors carry a better prognosis than standard glioblastomas.
 
==Molecular genetics==
By far, the most common structural deformity found is co-deletion of chromosomal arms 1p and 19q. The high frequency of co-deletion (60-80%) is a striking feature of this glial tumour, and is considered as a "genetic signature" of oligodendroglioma. 1p/19q deletion has been correlated with both chemosensitivity and improved prognosis in oligodendrogliomas.<ref>{{cite journal |author=Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M |title=[Molecular biology of oligodendroglial tumors] |language=French |journal=Neuro-Chirurgie |volume=51 |issue=3-4 Pt 2 |pages=260-8 |year=2005 |pmid=16292170 |doi=}}</ref><ref>{{cite journal |author=Walker C, Haylock B, Husband D, ''et al'' |title=Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors |journal=Neurology |volume=66 |issue=11 |pages=1661-7 |year=2006 |pmid=16769937 |doi=10.1212/01.wnl.0000218270.12495.9a}}</ref>
A t(1;19)(q10;p10) translocation mediates the combined deletions of 1p and 19q. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.
 
==Prognosis & treatment==
Oligodendrogliomas are generally felt to be incurable using current treatments.  However compared to the more common [[astrocytomas]], they are slowly growing with prolonged survival.  In one series, [[median]] survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III.<ref> Ohgaki H, Kleihues P. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15977639&query_hl=10&itool=pubmed_docsum Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.] ''J Neuropathol Exp Neurol''. 2005 Jun;64(6):479-89. PMID: 15977639</ref>  Because of the indolent nature of these tumors and the potential [[morbidity]] associated with [[neurosurgery]], [[chemotherapy]] and [[radiation therapy]], most [[oncology|neurooncologists]] will initially pursue a course of [[watchful waiting]] and treat patients symptomatically.  Symptomatic treatment often includes the use of [[anticonvulsants]] for seizures and [[Glucocorticoid|steroids]] for [[oedema|brain swelling]].  PCV chemotherapy ([[Procarbazine]], [[Lomustine|CCNU]] and [[Vincristine]]) has been shown to be effective and is currently the most commonly used chemotherapy regimen used for treating anaplastic oligodendrogliomas.<ref>Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D.[http://www.virtualtrials.com/pdf/oligo.pdf] p.452</ref> [[Temozolomide]] is a common chemotheraputic drug to which oligodendrogliomas appear to be quite sensitive.  It is often used as a first line therapy. 
 
Because of their diffusely infiltrating nature, oligodendrogliomas cannot be completely resected and are not curable by [[surgery|surgical excision]].  If the tumor mass compresses adjacent brain structures, a [[neurosurgery|neurosurgeon]] will typically remove as much of the tumor as he or she can without damaging other critical, healthy brain structures. Surgery may be followed up by [[chemotherapy]], [[radiation]], or a mix of both. Oligodendrogliomas, like all other infiltrating [[gliomas]], have a very high (almost uniform) rate of recurrence and gradually increase in grade over time.  Recurrent tumors are generally treated with more aggressive chemotherapy and radiation therapy. Recently, [[stereotactic surgery]] has proven successful in treating small tumors that have been diagnosed early.


Long-term survival is reported in a minority of patients.<ref>Tatter SB. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12392640&query_hl=7&itool=pubmed_DocSum Recurrent malignant glioma in adults.] ''Curr Treat Options Oncol''. 2002 Dec;'''3'''(6):509-24. PMID: 12392640,</ref> With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for both low grade and high grade oligodendrogliomas. In rare cases, patients have survived for up to fifteen years post-diagnosis. Westergaard’s
==Case Studies==
study (1997) showed that patients younger than 20 years had a median survival of 17.5 years.<ref>Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D.[http://www.virtualtrials.com/pdf/oligo.pdf] p.449</ref> Another study shows a 34% survival rate after 20 years. <ref> {{cite journal |author=Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA |title=Oligodendroglioma: does deferring treatment compromise outcome? |journal=Am. J. Clin. Oncol. |volume=26 |issue=3 |pages=e60-6 |year=2003 |pmid=12796617 |doi=10.1097/01.COC.0000072507.25834.D6}}</ref>
[[Oligodendroglioma case study one|Case #1]]
 
==References==
{{Reflist|2}}


{{Nervous tissue tumors}}
{{Nervous tissue tumors}}
{{SIB}}
[[de:Oligodendrogliom]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Neurological disorders]]
[[Category:Neurological disorders]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Neurosurgery]]
[[Category:Neurosurgery]]
[[Category:Oncology]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
[[Category:Oncology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Revision as of 23:21, 29 April 2019

For patient information click here.

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma

CDC on Oligodendroglioma

Oligodendroglioma in the news

Blogs on Oligodendroglioma

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Michael Maddaleni, B.S., Sujit Routray, M.D. [3]

Synonyms and keywords: Oligodendroglial tumor; oligodendroglial neoplasm; neoplasm of the oligodendroglia; oligodendroglial cancer; cancer of the oligodendroglia; oligodendroma; OD; ODs; oligoastroglioma; oligodendroblastoma

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effeciveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:Nervous tissue tumors


Template:WikiDoc Sources